Abstract
A combination therapy of metformin hydrochloride (MH) and repaglinide (RG) achieves a perfect glycemic control; however, the combination formulation of immediate release must be taken several times a day, compromising the therapeutic benefits and causing inconveniences to the patients. Herein, a bilayer matrix tablet that aimed at continuously releasing both MH and RG over time was developed, in which the two drugs were formulated into two separated layers. The tablets were prepared by wet granulation method, and the optimized formulation was obtained by evaluating the factors that affected the drug release. The bilayer tablets simultaneously released the two drugs over 12 h; and a better in vivo performance with a steady plasma concentration, markedly lower C max, prolonged T max, and perfect absorption was obtained. Summarily, the bilayer matrix tablets sustained both MH and RG release over time, thereby prolonging the actions for diabetic therapy and producing better health outcomes.
Similar content being viewed by others
References
De Berardis G, Dttorre A, Graziano G, Lucisano G, Pellegrini F, Cammarota S, et al. The burden of hospitalization related to diabetes mellitus: a population-based study. Nutr Metab Cardiovasc. 2013;22(7):605–12.
Zuo H, Shi Z, Hussain A. Prevalence, trends and risk factors for the diabetes epidemic in China: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2014;103(2):176–85.
Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103(2):176–85.
Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–46.
Thomas CR, Turner SL, Jefferson WH, Bailey CJ. Prevention of dexamethasone-induced insulin resistance by metformin. Biochem Pharmacol. 1998;56(9):1145–450.
Wolffenbuttel BHR. Repaglinide: a new compound for the treatment of patients with type 2 diabetes. Neth J Med. 1999;55(5):229–34.
Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;52(7):862–7.
Dailey GE. Glyburide/metformin tablets: a new therapeutic option for the management of type 2 diabetes. Expert Opin Pharmaco. 2003;4(8):1417–30.
Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(2):249–72.
Dhana lekshmi UM, Poovi G, Kishore N, Reddy PN. In vitro characterization and in vivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. Int J Pharm. 2010;396(1–2):194–203.
Lalau JD, Azzoug ML, Kajbaf F, Briet C, Desailloud R. Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. Diabetes Metab. 2014;40(3):220–3.
Klinzing G, Zavaliangos A. Understanding the effect of environmental history on bilayer tablet interfacial shear strength. Pharm Res. 2013;30(5):1300–10.
Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM. Review of bilayer tablet technology. Int J Pharm. 2014;461(1–2):549–58.
Qin C, He W, Zhu C, Wu M, Jin Z, Zhang Q, et al. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet. Int J Pharm. 2014;466(1–2):276–85.
Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ, et al. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev Ind Pharm. 2012;38(11):1371–80.
Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2012;64:163–74.
Wu B, Deng D, Lu Y, Wu W. Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. Eur J Pharm Biopharm. 2008;69(1):294–302.
Chambin O, Champion D, Debray C, Rochat-Gonthier MH, Le Meste M, Pourcelot Y. Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage. J Control Release. 2004;95(1):101–8.
Grund J, Körberr M, Bodmeier R. Predictability of drug release from water-insoluble polymeric matrix tablets. Eur J Pharm Biopharm. 2013;85(3):650–5.
Rujivipat S, Bodmeier R. Modified release from hydroxypropyl methylcellulose compression-coated tablets. Int J Pharm. 2010;402(1–2):72–7.
Quinten T, Gonnissen Y, Adriaens E, Beer TD, Cnudde V, Masschaele B, et al. Development of injection moulded matrix tablets based on mixtures of ethylcellulose and low-substituted hydroxypropylcellulose. Eur J Pharm Sci. 2009;37(3–4):207–16.
Sotthivirat S, Haslam JL, Lee PI, Rao VM, Stella VJ. Release mechanisms of a sparingly water-soluble drug from controlled porosity-osmotic pump pellets using sulfobutylether-beta-cyclodextrin as both a solubilizing and osmotic agent. J Pharm Sci. 2009;98(6):1992–2000.
Palmer D, Levina M, Nokhodchi A, Douroumis D, Farrell T, Rajabi-Siahboomi A. The influence of sodium carboxymethylcellulose on drug release from polyethylene oxide extended release matrices. AAPS PharmSciTech. 2011;12(3):862–71.
Conti S, Maggi L, Segale L, Ochoa Machiste E, Conte U, Grenier P, et al. Matrices containing NaCMC and HPMC 1. Dissolution performance characterization. Int J Pharm. 2007;333(1–2):136–42.
Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release. 2011;154(1):2–19.
Vaidya MP, Avachat AM. Investigation of the impact of insoluble diluents on the compression and release properties of matrix based sustained release tablets. Powder Technol. 2011;214(3):375–81.
Fuertes I, Caraballo I, Miranda A, Milln M. Study of critical points of drugs with different solubilities in hydrophilic matrices. Int J Pharm. 2010;383(1–2):138–46.
Mandi Z, Gabelica V. Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal. 2006;41(3):866–71.
American Chemical Society. 2014. https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf.
Bettini R, Catellani PL, Santi P, Massimo G, Peppas NA, Colombo P. Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate. J Control Release. 2001;70(3):383–91.
Vidon N, Chaussade S, Noel M, Franchisseur C, Huchet B, Bernier JJ. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988;4(3):223–9.
Nayak AK, Pal D, Santra K. Tamarind seed polysaccharide-gellan mucoadhesive beads for controlled release of metformin HCl. Carbohydr Polym. 2014;103:154–63.
Kortejrvi H, Mikkola J, Bckman M, Antila S, Marvola M. Development of level A, B and C in vitro–in vivo correlations for modified-release levosimendan capsules. Int J Pharm. 2002;241(1):87–95.
Acknowledgments
This work was supported by the Creation of Major New Drugs national major projects (2011ZX09202-101-24, 2012ZX09202101-008, 2014ZX09507004-001), and the “333” High Level Talents Cultivation Project of Jiangsu Province.
Author information
Authors and Affiliations
Corresponding author
Additional information
W. He, S.J. Huang, and C.Y. Zhou contributed equally to this work.
Rights and permissions
About this article
Cite this article
He, W., Huang, S., Zhou, C. et al. Bilayer Matrix Tablets for Prolonged Actions of Metformin Hydrochloride and Repaglinide. AAPS PharmSciTech 16, 344–353 (2015). https://doi.org/10.1208/s12249-014-0229-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-014-0229-1